{"id":3755,"date":"2021-02-08T12:30:38","date_gmt":"2021-02-08T12:30:38","guid":{"rendered":"https:\/\/www.thervacb.eu\/%e5%aa%92%e4%bd%93%e4%b8%ad%e5%bf%83\/%e8%b7%9f%e7%9d%80%e6%88%91%e4%bb%ac%ef%bc%81\/"},"modified":"2023-05-09T12:12:31","modified_gmt":"2023-05-09T11:12:31","slug":"%e8%b7%9f%e7%9d%80%e6%88%91%e4%bb%ac%ef%bc%81","status":"publish","type":"page","link":"https:\/\/www.thervacb.eu\/zh-hans\/%e5%aa%92%e4%bd%93%e4%b8%ad%e5%bf%83\/%e8%b7%9f%e7%9d%80%e6%88%91%e4%bb%ac%ef%bc%81\/","title":{"rendered":"\u8ddf\u7740\u6211\u4eec\uff01"},"content":{"rendered":"

[et_pb_section fb_built=”1″ fullwidth=”on” _builder_version=”4.2.1″ da_disable_devices=”off|off|off” global_colors_info=”{}” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_fullwidth_slider use_text_overlay=”on” text_overlay_color=”rgba(6,66,58,0.25)” _builder_version=”4.4.4″ custom_padding=”83px||65px|||” auto=”on” auto_ignore_hover=”on” global_colors_info=”{}”][et_pb_slide heading=”\u901a\u8fc7Twitter\u5173\u6ce8\u6211\u4eec” button_text=”\u53bb\u63a8\u7279” button_link=”https:\/\/twitter.com\/TherVacB_EU” url_new_window=”on” use_bg_overlay=”off” use_text_overlay=”on” arrows_custom_color=”#2d788c” dot_nav_custom_color=”#2d788c” text_border_radius=”10px” _builder_version=”4.4.4″ header_font=”|700|||||||” header_text_align=”center” body_text_align=”center” background_enable_color=”off” use_background_color_gradient=”on” background_color_gradient_start=”rgba(0,0,0,0)” background_color_gradient_end=”rgba(0,0,0,0)” background_color_gradient_direction=”90deg” background_color_gradient_overlays_image=”on” background_image=”https:\/\/www.thervacb.eu\/wp-content\/uploads\/thervacb-labor_copyright-kurt-bauer-photojournalist.jpg” background_enable_image=”on” text_orientation=”center” header_text_shadow_style=”preset1″ header_text_shadow_color=”#706f6f” body_text_shadow_style=”preset1″ body_text_shadow_color=”#706f6f” text_shadow_style=”preset1″ text_shadow_color=”#706f6f” global_colors_info=”{}” sticky_transition=”on”][\/et_pb_slide][\/et_pb_fullwidth_slider][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.2.1″ da_disable_devices=”off|off|off” global_colors_info=”{}” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row _builder_version=”4.2.1″ global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.2.1″ global_colors_info=”{}”][et_pb_text _builder_version=”4.11.3″ hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n\n\n

\n\t\n \n
\n \n
\n

\n TherVacB Project<\/span>\n <\/span>\n Follow<\/span>\n \n <\/path><\/svg>736<\/span>\n <\/path><\/svg>1,108<\/span>\n <\/span>\n <\/p>\n

\n EU-funded #H2020 project developing a therapeutic vaccine to cure #HepatitisB.\n\ud83e\udd8bhttps:\/\/t.co\/THT7rFlHR8 | \ud83d\udcfayt\/@TherVacB | \ud83d\udd17Linkedin\/company\/thervacb-project <\/p>\n <\/div>\n

\n
\n \n\t\t\t<\/svg> <\/div>\n \"TherVacB_EU\"\n <\/div>\n <\/a>\n<\/div>\n\n
\n \n
\n\n
\n <\/path><\/svg>Retweet on Twitter<\/span><\/a>\n TherVacB Project Retweeted<\/a>\n<\/div>\n\n
\n
\n \n \"HepBFoundation;\n <\/a>\n \n Hepatitis B Foundation<\/a>\n @HepBFoundation<\/a>\n \n \t\t ·<\/span>\n\t
\n 4 8 \u6708 2084640936907141296<\/span><\/a>\n <\/div>\n <\/div>\n
\n \n\t\t\t<\/svg> <\/div>\n <\/div>\n\n
\n \t\t\t\t

#BLOG: New hepatitis delta drug, Hepcludex, now approved in the U.S.
\n
\n\ud83e\uddec Big news in liver health: the FDA has approved #Hepcludex (bulevirtide) for hepatitis delta, the most severe form of viral hepatitis.
\n
\nRead the full story on our blog \ud83d\udc47
\nhttps:\/\/www.hepb.org\/blog\/
\n
\n#FDA <\/p>\n\t\t\t\t\t\t\n \n

\n \n \n <\/path><\/svg> \n \"Image\n \n Twitter feed image.<\/span> <\/a>\n \n <\/div>\n\n\t \n \n <\/div>\n \n\t\n
\n \n <\/path><\/g><\/svg> Reply on Twitter 2084640936907141296<\/span>\n <\/a>\n\n \n <\/path><\/svg> Retweet on Twitter 2084640936907141296<\/span>\n 2<\/span>\n <\/a>\n\n \n <\/path><\/g><\/svg> Like on Twitter 2084640936907141296<\/span>\n 1<\/span>\n <\/a>\n\n \n Twitter<\/span>\n 2084640936907141296<\/span>\n <\/a>\n \n\t<\/div>\n\n\t<\/div>\n\n\n
\n\n
\n <\/path><\/svg>Retweet on Twitter<\/span><\/a>\n TherVacB Project Retweeted<\/a>\n<\/div>\n\n
\n
\n \n \"gavi;\n <\/a>\n \n Gavi, the Vaccine Alliance<\/a>\n <\/path><\/svg><\/span>\n @gavi<\/a>\n \n \t\t ·<\/span>\n\t
\n 5 8 \u6708 2085018381833347219<\/span><\/a>\n <\/div>\n <\/div>\n
\n \n\t\t\t<\/svg> <\/div>\n <\/div>\n\n
\n \t\t\t\t

Which vaccines have had the biggest impact on preventing deaths and keeping people healthy?
\n
\nResearchers compared 14 vaccine programmes across 117 countries, and found that HPV and measles vaccine programmes came out on top in terms of deaths and disease prevented. The <\/p>\n\t\t\t\t\t\t\n \n

\n \n \n <\/path><\/svg> \n \"Image\n \n Twitter feed image.<\/span> <\/a>\n \n <\/div>\n\n\t \n \n <\/div>\n \n\t\n
\n \n <\/path><\/g><\/svg> Reply on Twitter 2085018381833347219<\/span>\n <\/a>\n\n \n <\/path><\/svg> Retweet on Twitter 2085018381833347219<\/span>\n 22<\/span>\n <\/a>\n\n \n <\/path><\/g><\/svg> Like on Twitter 2085018381833347219<\/span>\n 39<\/span>\n <\/a>\n\n \n Twitter<\/span>\n 2085018381833347219<\/span>\n <\/a>\n \n\t<\/div>\n\n\t<\/div>\n\n\n
\n\n
\n <\/path><\/svg>Retweet on Twitter<\/span><\/a>\n TherVacB Project Retweeted<\/a>\n<\/div>\n\n
\n
\n \n \"LiverFellow;\n <\/a>\n \n Liver Fellow Network<\/a>\n @LiverFellow<\/a>\n \n \t\t ·<\/span>\n\t
\n 5 8 \u6708 2085098645527933308<\/span><\/a>\n <\/div>\n <\/div>\n
\n \n\t\t\t<\/svg> <\/div>\n <\/div>\n\n
\n \t\t\t\t

\ud83d\udea8 #LFNQoTW | Question 4
\n
\nA 51-year-old woman comes to establish care at your clinic.
\n
\nWhich of the following statements is true about this patient?
\n
\nSelect your answer in the poll below \ud83d\udc47
\n
\nAnswer will be posted on Friday \ud83d\uddd3\ufe0f
\n
\n#LFN #MedEd #Hepatology <\/p>\n\t\t\t\t\t\t\n \n

\n \n \n <\/path><\/svg> \n \"Image\n \n Twitter feed image.<\/span> <\/a>\n \n <\/div>\n\n\t \n \n <\/div>\n \n\t\n
\n \n <\/path><\/g><\/svg> Reply on Twitter 2085098645527933308<\/span>\n <\/a>\n\n \n <\/path><\/svg> Retweet on Twitter 2085098645527933308<\/span>\n 4<\/span>\n <\/a>\n\n \n <\/path><\/g><\/svg> Like on Twitter 2085098645527933308<\/span>\n 23<\/span>\n <\/a>\n\n \n Twitter<\/span>\n 2085098645527933308<\/span>\n <\/a>\n \n\t<\/div>\n\n\t<\/div>\n\n\n
\n\n
\n <\/path><\/svg>Retweet on Twitter<\/span><\/a>\n TherVacB Project Retweeted<\/a>\n<\/div>\n\n
\n
\n \n \"EASLedu;\n <\/a>\n \n EASL Education<\/a>\n <\/path><\/svg><\/span>\n @EASLedu<\/a>\n \n \t\t ·<\/span>\n\t
\n 4 8 \u6708 2084576074260762822<\/span><\/a>\n <\/div>\n <\/div>\n
\n \n\t\t\t<\/svg> <\/div>\n <\/div>\n\n
\n \t\t\t\t

Ready to lead your own research group? \ud83d\udd2c
\n
\nThe science may be familiar but what about managing a team, securing funding, building a research programme and planning a sustainable career?\ud83e\udee3
\n
\nThe next episode of #TalkLiverToMe explores what research independence really looks like. <\/p>\n\t\t\t\t\t\t\n \n

\n \n <\/path><\/svg> \n \n \n\t\t\t\t\t\"Image\n\t\t\t\t\t<\/video>\n\n \n \n Twitter feed video.<\/span> \n <\/div>\n\n\t \n \n <\/div>\n \n\t\n
\n \n <\/path><\/g><\/svg> Reply on Twitter 2084576074260762822<\/span>\n <\/a>\n\n \n <\/path><\/svg> Retweet on Twitter 2084576074260762822<\/span>\n 3<\/span>\n <\/a>\n\n \n <\/path><\/g><\/svg> Like on Twitter 2084576074260762822<\/span>\n 5<\/span>\n <\/a>\n\n \n Twitter<\/span>\n 2084576074260762822<\/span>\n <\/a>\n \n\t<\/div>\n\n\t<\/div>\n\n <\/div>\n\n Load More<\/span><\/a>\n\n<\/span>